Drug Profile
AV MEL 1
Alternative Names: AV-MEL-1Latest Information Update: 28 Jan 2024
Price :
$50
*
At a glance
- Originator AiVita Biomedical
- Class Cancer vaccines; Cell therapies; Dendritic cell vaccines; Immunotherapies
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Malignant melanoma
Most Recent Events
- 28 Jan 2024 No recent reports of development identified for phase-I development in Malignant-melanoma(Combination therapy, First-line therapy, Late-stage disease, Metastatic disease) in USA (Parenteral, Injection)
- 24 Jan 2023 No development reported - Phase-II for Malignant melanoma (Late-stage disease) in USA (Parenteral)
- 01 Dec 2020 Phase-I clinical trials in Malignant melanoma (Combination therapy, First-line therapy, Metastatic disease, Late-stage disease) in USA (Parenteral) (NCT03743298)